Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Tim E Peto
Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19
1 Deeks J Raffle A Gill M Covid-19: government must urgently rethink lateral flow test roll out. The use of rapid lateral flow antigen testing (LFT) for SARS-CoV-2 has been questioned, , with uncorroborated 4 Fearon E Davis E Stage H et al. A response to “Covid-19: Controversial rapid test policy divides doctors and scientists”. reports of poor LFT sensitivity.
COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing
Abstract Background Lateral flow device (LFD) viral antigen immunoassays have been developed around the world as diagnostic tests for SARS-CoV-2 infection. They have been proposed to deliver an infrastructure-light, cost-economical solution giving results within half an hour. Methods LFDs were initially reviewed by a Department of Health and Social Care team, part of the UK government, from which 64 were selected for further evaluation from 1st August to 15th December 2020.
Rapid triage for COVID-19 using routine clinical data for patients attending hospital: development and prospective validation of an artificial intelligence screening test
Evidence before this study A detailed systematic review identified 91 diagnostic models for COVID-19 as of July 1, 2020; however, all were appraised to be at “high risk of bias”. Existing early detection models overwhelmingly consider radiological imaging (60 of 91 models), such as CT, which is less readily available than blood tests and involves exposure of patients to ionising radiation.
Identifying Mixed Mycobacterium tuberculosis Infection and Laboratory Cross-Contamination during Mycobacterial Sequencing Programs
Mycobacteriology and Aerobic Actinomycetes David H. Wyllie, Esther Robinson, Tim Peto, Derrick W. Crook, Adebisi Ajileye, Priti Rathod, Rosemarie Allen, Lisa Jarrett, E. Grace Smith, A. Sarah Walker Betty A. Forbes, Editor DOI: 10.1128/JCM.00923-18 Article Information History Received June 11, 2018 Returned for modification August 2, 2018 Accepted August 28, 2018 Published online October 25, 2018. Copyright & Usage Copyright © 2018 Wyllie et al.
Control of Artifactual Variation in Reported Intersample Relatedness during Clinical Use of a Mycobacterium tuberculosis Sequencing Pipeline
ABSTRACTContact tracing requires reliable identification of closely related bacterial isolates. When we noticed the reporting of artifactual variation between Mycobacterium tuberculosis isolates during routine next-generation sequencing of Mycobacterium spp., we investigated its basis in 2,018 consecutive M. tuberculosis isolates.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Tim E
Contact Tim E, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack